Program
Anti-PD-1/Anti-VEGFR2 Bispecific Antibody OTP-01
Its studies are led by Ottimo Pharma.
Furthest: phase 2, since Nov 16, 20251 company-led study, 1 open or runningNext primary completion: Dec 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ottimo Pharma | 11 open or running | phase 2since Nov 16, 2025 | Nov 16, 2025 | Dec 2028phase 2 · NCT07266428 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 16, 2025First study: phase 2 study in Advanced Solid TumorsFirst studyNCT07266428 · 170 planned · United States, Australia, Brazil and more
Ahead
- Dec 2028Primary completion: phase 2 study in Advanced Solid TumorsNCT07266428
TargetBeta
“An immunoglobulin G1 (IgG1) Fc-null bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor receptor 2 (VEGFR2; VEGFR-2), ”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07266428Advanced Solid Tumors · United States, Australia, Brazil and more | 2 | Recruiting | Dec 2028 | 170 |
How it is read
Names in the registry
- “OTP-01”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.